Merck follows Opdivo’s suit, prices Keytruda in China at half its U.S. tag: report
admin 19th September 2018 Uncategorised 0When Bristol-Myers Squibb priced Opdivo in China at half the U.S. cost, industry watchers considered it a benchmark against which future immuno-oncology therapies will measure. Now it appears at least its archenemy, Merck & Co., has taken note for PD-1 rival Keytruda.
More: Merck follows Opdivo’s suit, prices Keytruda in China at half its U.S. tag: report
Source: fierce